Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients
NCT ID: NCT05119686
Last Updated: 2023-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
140 participants
INTERVENTIONAL
2021-11-16
2022-11-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
NCT06439602
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
NCT06846515
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
NCT05253833
Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients
NCT04155918
Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia
NCT06603142
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
AR882 Dose 1 x 12 weeks
AR882 Dose 1
Solid Oral Capsule
Group 2
AR882 Dose 1 x 2 weeks, then Dose 2 x 10 weeks
AR882 Dose 1
Solid Oral Capsule
AR882 Dose 2
Solid Oral Capsule
Group 3
AR882 matching placebo x 12 weeks
Placebo
Matching Solid Oral Capsule Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AR882 Dose 1
Solid Oral Capsule
AR882 Dose 2
Solid Oral Capsule
Placebo
Matching Solid Oral Capsule Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* sUA \> 7 mg/dL
* Estimated Glomerular Filtration Rate (eGFR) ≥ 30 mL/min/1.73m2
Exclusion Criteria
* History of cardiac abnormalities
* History of kidney stones
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arthrosi Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
R Keenan, MD
Role: STUDY_CHAIR
Arthrosi Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arthrosi Investigative Site
Gilbert, Arizona, United States
Arthrosi Investigative Site
Sun City, Arizona, United States
Arthrosi Investigative Site
Tucson, Arizona, United States
Arthrosi Investigative Site
Miami, Florida, United States
Arthrosi Investigative Site
Miami Lakes, Florida, United States
Arthrosi Investigative Site
Tampa, Florida, United States
Arthrosi Investigative Site
Honolulu, Hawaii, United States
Arthrosi Investigative Site
Overland Park, Kansas, United States
Arthrosi Investigative Site
Cleveland, Ohio, United States
Arthrosi Investigative Site
Cleveland, Ohio, United States
Arthrosi Investigative Site
Duncansville, Pennsylvania, United States
Arthrosi Investigative Site
Dallas, Texas, United States
Arthrosi Investigative Site
Houston, Texas, United States
Arthrosi Investigative Site
Tomball, Texas, United States
Arthrosi Investigative Site
West Jordan, Utah, United States
Arthrosi Investigative Site
Glendale, Wisconsin, United States
Arthrosi Investigative Site
Melbourne, Camberwell, Australia
Arthrosi investigative Site
Botany, New South Wales, Australia
Arthrosi Investigative Site
Taichung, , Taiwan
Arthrosi Investigative Site - 301
Taipei, , Taiwan
Arthrosi Investigative Site - 304
Taipei, , Taiwan
Arthrosi Investigative Site
Taipei, , Taiwan
Arthrosi Investigative Site
Taoyuan District, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AR882-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.